非侵入性產前檢測市場規模、佔有率、成長分析（按產品、檢測方法、技術、妊娠風險、妊娠週齡、應用和地區分類）- 產業預測，2025 年至 2032 年

2023 年全球無創產前檢測 (NIPT) 市場規模價值 38 億美元，預計將從 2024 年的 41.6 億美元成長到 2032 年的 86.7 億美元，預計到 2032 年將達到 12 億美元。複合年成長率為9.6%。

非侵入性腸外篩檢市場主要集中在非侵入性產前檢測(NIPT)，受技術進步和母親年齡成長的推動，該市場已顯示出顯著的成長，這與更高的染色體異常風險相關。這種基因檢測方法分析母體血清中的胎兒無細胞DNA，可以早期發現唐氏症和透納氏症疾病。目前，世界各地廣泛使用多種 NIPT，包括 MaterniT21 PLUS、Harmony 和 Panorama。隨著 NIPT 報銷額度的提高以及向非侵入性方法的轉變，市場有望擴張。然而，合格人員短缺和嚴格的監管要求等挑戰可能會阻礙進展。新興市場，特別是亞太地區，為該領域的成長提供了新的機會。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和資料資料
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管格局
• 案例研究
• 技術進步

全球無創產前檢測 (NIPT) 市場規模（按產品）

• 市場概況
• 耗材
• 試劑
• 裝置

全球無創產前檢測 (NIPT) 市場規模（按檢測方法）

• 市場概況
• 超音波檢測
• 生化篩檢測試
• 母體血漿中的遊離 DNA 檢測

全球無創產前檢測 (NIPT) 市場規模（按技術）

• 市場概況
• NGS
• 陣列技術
• PCR
• 其他

全球無創產前檢測 (NIPT) 市場規模（按懷孕風險）

• 市場概況
• 高風險
• 平均風險
• 低風險

全球無創產前檢測 (NIPT) 市場規模（按孕齡）

• 市場概況
• 0 - 12 週
• 13-24 週
• 25-36 週

全球無創產前檢測 (NIPT) 市場規模（按應用）

• 市場概況
• 三體性
• 微缺失症候群
• 其他

全球無創產前檢測 (NIPT) 市場規模（按最終用戶）

• 市場概況
• 醫院
• 診所
• 診斷實驗室
• 其他

全球無創產前檢測 (NIPT) 市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較（2022-2024 年）

主要企業簡介

• Berry Genomics Co. Ltd.（China）
• BGI Genomics Co., Ltd.（China）
• Eurofins LifeCodexx GmbH（Germany）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• GE Healthcare（United States）
• Natera, Inc.（United States）
• Laboratory Corporation of America Holdings（LabCorp）（United States）
• Illumina, Inc.（United States）
• Myriad Genetics, Inc.（United States）
• Quest Diagnostics Incorporated（United States）
• Thermo Fisher Scientific Inc.（United States）
• Sonic Healthcare Limited（Australia）
• Centogene NV（Germany）
• PerkinElmer, Inc.（United States）
• Cordlife Group Limited（Singapore）

結論和建議

Global Non-Invasive Prenatal Testing (NIPT) Market size was valued at USD 3.8 billion in 2023 and is poised to grow from USD 4.16 billion in 2024 to USD 8.67 billion by 2032, growing at a CAGR of 9.6% during the forecast period (2025-2032).

The non-invasive parenteral screening market, predominantly focused on non-invasive prenatal testing (NIPT), is witnessing significant growth driven by advancements in technology and increasing maternal age, which correlates with higher risks for chromosomal abnormalities. This genetic testing method analyzes fetal cell-free DNA in maternal blood serum, enabling early detection of conditions such as Down syndrome and Turner syndrome. Various NIPTs, including MaterniT21 PLUS, Harmony, and Panorama, are now widely available globally. Facilitated by rising reimbursements for NIPT and a shift towards non-invasive methods, the market is poised for expansion. However, challenges such as a lack of qualified personnel and stringent regulatory requirements may impede progress. Emerging markets, especially in the Asia-Pacific region, present new opportunities for growth in this sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Non-Invasive Prenatal Testing (Nipt) market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Non-Invasive Prenatal Testing (NIPT) Market Segmental Analysis

Global Non-Invasive Prenatal Testing (NIPT) Market is segmented by Product, Testing Method, Technology, Pregnancy Risk, Gestation Period, Application, End User and region. Based on Product, the market is segmented into Consumables, Reagents and Instruments. Based on Testing Method, the market is segmented into Ultrasound Detection, Biochemical Screening Tests and Cell-Free DNA in Maternal Plasma Tests. Based on Technology, the market is segmented into NGS, Array Technology, PCR and Others. Based on Pregnancy Risk, the market is segmented into High Risk, Average Risk and Low Risk. Based on Gestation Period, the market is segmented into 0-12 Weeks, 13-24 Weeks and 25-36 Weeks. Based on Application, the market is segmented into Trisomy, Microdeletion Syndrome and Others. Based on End User, the market is segmented into Hospitals, Clinics, Diagnostic Laboratories and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Non-Invasive Prenatal Testing (NIPT) Market

The Global Non-Invasive Prenatal Testing (NIPT) market is driven by the increasing demand for precise and advanced screening techniques that enable early detection of genetic disorders in infants. Companies are focusing on developing innovative noninvasive diagnostic solutions and forming strategic partnerships to enhance their presence in the market. Recent progress in human genome sequencing has significantly improved the identification of aneuploidies in newborns. Notably, Progenity, Inc. launched the Resura Prenatal Diagnostic for Monogenic Disease in 2019, marking a milestone as the first flexible, noninvasive test for single-gene conditions. Furthermore, many countries are adopting non-invasive prenatal screening protocols to effectively detect chromosomal abnormalities.

Restraints in the Global Non-Invasive Prenatal Testing (NIPT) Market

The growth of the Global Non-Invasive Prenatal Testing (NIPT) market faces several significant restraints, primarily stemming from economic and educational barriers. High testing costs, particularly in developing nations where prices range from USD 350 to USD 400, render these tests unaffordable for many, thus hindering widespread adoption. Additionally, a general lack of awareness regarding genetic disorders among the population in emerging markets further complicates acceptance. Coupled with decreasing per capita healthcare expenditure and insufficient reimbursement policies for these tests, these factors collectively contribute to a constrained growth environment for the NIPT market on a global scale.

Market Trends of the Global Non-Invasive Prenatal Testing (NIPT) Market

The Global Non-Invasive Prenatal Testing (NIPT) market is witnessing significant growth as healthcare trends increasingly favor non-invasive methodologies over traditional invasive procedures. Advances in technology and clinical validation have positioned NIPT as the preferred choice for prenatal screening, driven by its therapeutic benefits and cost-effectiveness. Regulatory frameworks in various countries, such as the Netherlands, have further reinforced the adoption of non-invasive diagnostics, establishing them as standard practice. This surge in utilization highlights a shift toward safer prenatal options, with NIPT rapidly gaining traction worldwide, despite the ongoing relevance of invasive tests for specific medical conditions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Non-Invasive Prenatal Testing (NIPT) Market Size by Product & CAGR (2025-2032)

• Market Overview
• Consumables
• Reagents
• Instruments

Global Non-Invasive Prenatal Testing (NIPT) Market Size by Testing Method & CAGR (2025-2032)

• Market Overview
• Ultrasound Detection
• Biochemical Screening Tests
• Cell-Free DNA in Maternal Plasma Tests

Global Non-Invasive Prenatal Testing (NIPT) Market Size by Technology & CAGR (2025-2032)

• Market Overview
• NGS
• Array Technology
• PCR
• Others

Global Non-Invasive Prenatal Testing (NIPT) Market Size by Pregnancy Risk & CAGR (2025-2032)

• Market Overview
• High Risk
• Average Risk
• Low Risk

Global Non-Invasive Prenatal Testing (NIPT) Market Size by Gestation Period & CAGR (2025-2032)

• Market Overview
• 0-12 Weeks
• 13-24 Weeks
• 25-36 Weeks

Global Non-Invasive Prenatal Testing (NIPT) Market Size by Application & CAGR (2025-2032)

• Market Overview
• Trisomy
• Microdeletion Syndrome
• Others

Global Non-Invasive Prenatal Testing (NIPT) Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Diagnostic Laboratories
• Others

Global Non-Invasive Prenatal Testing (NIPT) Market Size & CAGR (2025-2032)

• North America (Product, Testing Method, Technology, Pregnancy Risk, Gestation Period, Application, End User)
  • US
  • Canada
• Europe (Product, Testing Method, Technology, Pregnancy Risk, Gestation Period, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Testing Method, Technology, Pregnancy Risk, Gestation Period, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Testing Method, Technology, Pregnancy Risk, Gestation Period, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Testing Method, Technology, Pregnancy Risk, Gestation Period, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Berry Genomics Co. Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BGI Genomics Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins LifeCodexx GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Natera, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Laboratory Corporation of America Holdings (LabCorp) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics Incorporated (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sonic Healthcare Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Centogene N.V. (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cordlife Group Limited (Singapore)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations